Developer docs
API playgroundTry for free, no card

Search company profiles

Protean BioDiganostics Inc

Full company profile

uuid00044zf

Namestring
Protean BioDiganostics Inc
Legal namestring
Protean BioDiagnostics Inc
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Protean BioDiagnostics Inc is a privately held precision oncology diagnostics company founded by Dr. Anthony M. Magliocco and headquartered in Orlando, Florida, where it operates a CAP/CLIA-certified high-complexity clinical laboratory. The company delivers advanced cancer diagnostic testing, hereditary cancer risk assessment, and treatment-decision support primarily to community-based oncologists, hospital and health-system laboratories, cancer patients, and pharmaceutical/CRO partners. Its proprietary platform, Protean MAPS (Multi-Omic Analysis and Precision Medicine System), integrates multiple diagnostic modalities — tissue testing, liquid biopsy, genetic testing, methylation/epigenetic analysis, and digital pathology imaging — with telemedicine-backed decision support and AI clinical trial matching, and is positioned as the only comprehensive precision medicine system explicitly designed for community-based cancer patients.

The technology stack is largely assembled through strategic partnerships and licensing rather than wholly internal development. Core offerings include Risk MAPS (whole exome sequencing-based hereditary risk assessment), Aventa FusionPlus (a 3D genomics clinical test for gene fusions across 361 genes, developed via the Aventa Genomics joint venture with Arima Genomics), CDX Prostate (AI-powered prostate cancer risk scoring via Nanostics' ClarityDX platform), HDPCR NSCLC Assay (ChromaCode multiplexing), Travera Rapid Therapy Guidance (functional profiling of live tumor cells against FDA-approved therapies), and the Pictor ENA IgG Multiplex ELISA for autoimmune disease. Additional capabilities include variant annotation pipelines interoperating with Roche NAVIFY, SOPHiA DDM, QIAGEN Clinical Insight Interpret, and Genoox, as well as a CLIA Digital Pathology Imaging Laboratory using computer-vision-based image analysis.

The company generates revenue primarily on a fee-for-service laboratory testing basis, billing physicians, hospitals, insurance, and patients per test with quote-based pricing that is not publicly disclosed. A secondary revenue stream comes from contract research organization (CRO) services covering CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology clients. Protean employs 51-100 staff, holds state laboratory licensure in Florida, California, and New York, and has operated with minimal disclosed external capital — a single disclosed funding round of $330,000 in 2019 — supplemented by non-dilutive support from the Florida SBDC at UCF and the UCF Business Incubation Program at Lake Nona.

Short descriptiontext

Protean BioDiagnostics is a CAP/CLIA-certified precision oncology laboratory in Orlando, Florida, operating the proprietary Protean MAPS platform that integrates multi-omic cancer profiling, AI-powered clinical trial matching, telemedicine decision support, and hereditary risk assessment for community oncologists, hospitals, and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOrlando, United States
HQ citystring
Orlando
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology diagnostics, cancer profiling services, clinical laboratory testing, hereditary cancer screening, companion diagnostics development
Industry3 codes
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Clinical Laboratory Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Laboratory Testing Services
TypeTransaction Fee
Description

Protean operates a CAP/CLIA-accredited, high-complexity laboratory performing cancer diagnostic tests for physicians, hospitals, and patients. Revenue is generated through fee-for-service laboratory testing billed to healthcare providers, insurance, and patients.

proteanbiodx.com
2Genetic Risk Assessment Testing
TypeTransaction Fee
Description

Risk MAPS™ hereditary cancer testing services using cheek swab samples with whole exome sequencing analysis, billed as laboratory services.

proteanbiodx.com
3Research Services
TypeProfessional Services
Description

CRO services including CLIA development, clinical trials support, and companion diagnostics development for pharmaceutical and biotechnology partners.

proteanbiodx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Clinical laboratory testing services - quote-based pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Fee-for-service laboratory testing. Specific pricing not publicly disclosed; requires direct inquiry for test pricing and billing information.

proteanbiodx.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Protean MAPS
Description

Proprietary comprehensive cancer profiling system integrating screening, diagnostics, treatment guidance, and telemedicine decision support for community-based cancer patients.

proteanbiodx.com
+1 more record
Core offering1 text field

Protean BioDiagnostics operates a CAP/CLIA-certified clinical laboratory in Orlando, Florida, that delivers precision oncology diagnostic testing and cancer profiling through its proprietary Protean MAPS platform. The company sells cancer screening, hereditary genetic testing (Risk MAPS), AI-powered prostate cancer risk assessment (CDX Prostate), 3D genomics gene fusion testing (Aventa FusionPlus), lung cancer diagnostics (HDPCR NSCLC Assay), functional therapy guidance (Travera), autoimmune diagnostics (Pictor ENA), and telemedicine-backed oncology consultations. It also provides CRO services including CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Aventa FusionPlus detected potentially actionable variants in half of previously characterized tumor specimens with no known actionable driver
+1 more record
Product overview1 text field

Protean BioDiagnostics offers Protean MAPS as the core comprehensive cancer profiling platform that integrates health screening, diagnostics, treatment guidance, and telemedicine-backed decision support. The platform encompasses multiple specialized products: Risk MAPS for hereditary cancer risk assessment via whole exome sequencing; CDX Prostate (via Nanostics partnership) for AI-powered prostate cancer risk scoring; Aventa FusionPlus (joint venture with Arima Genomics) as the first 3D genomics test for solid tumors; HDPCR NSCLC Assay (with ChromaCode) for rapid lung cancer diagnostics; Travera Rapid Therapy Guidance for treatment response profiling; and Pictor ENA IgG Multiplex ELISA for autoimmune diagnostics. Services include cancer consultations, CRO services, research services, methylation/epigenetics testing, CLIA development, and clinical trials support. All services are delivered through their CAP/CLIA-certified laboratory in Orlando, Florida.

Product and service12 records
1Protean MAPS
CategoryCore Platform / Cancer Profiling System
Description

Proprietary cancer profiling system that incorporates the highest quality tests available and delivers rapid results with decision support and precision oncology guidance for all cancer types; includes telemedicine, virtual tumor boards, and AI clinical trial matching for oncologists and patients.

2Risk MAPS Hereditary Cancer Testing
CategoryHereditary Cancer Genetic Testing
Description

Whole exome sequencing-based hereditary cancer risk assessment offering unprecedented coverage of the human genome for cancer prevention and treatment planning; cheek swab sample collection enables at-home or in-office testing for patients and at-risk individuals.

3CDX Prostate (ClarityDX Prostate)
CategoryAI-powered Cancer Diagnostic Test
Description

Blood-based AI-powered diagnostic test for men at risk of aggressive prostate cancer, used as a reflex test following elevated PSA or abnormal DRE; uses biological data, clinical information, and machine learning models to generate risk scores. Performed in Protean's CLIA-certified Orlando laboratory.

4Aventa FusionPlus
Category3D Genomics Diagnostic Test
Description

First 3D genomics clinical test detecting gene fusions, translocations, and rearrangements across 361 genes from FFPE tumor tissue using spatial proximity preservation for 100-1000x signal amplification; developed via the Aventa Genomics joint venture between Arima Genomics and Protean.

5HDPCR NSCLC Assay
CategoryLung Cancer Diagnostic Test
Description

Non-small cell lung cancer assay based on ChromaCode's High Definition PCR (HDPCR) multiplexing technology delivering rapid turnaround and clinically relevant markers for lung cancer diagnostics; addresses cost, turnaround, and tissue sample barriers in NSCLC.

6Travera Rapid Therapy Guidance
CategoryFunctional Therapy Guidance Test
Description

Functional profiling test that uses tissue or fluid to screen live tumor cells against approved anti-cancer therapies; indicated for 39 different cancers and 100+ FDA-approved therapies to guide treatment selection for advanced carcinoma patients.

7Pictor PictHealth ENA IgG Multiplex ELISA
CategoryAutoimmune Disease Diagnostic Test
Description

Next-generation multiplexed ELISA test for autoimmune disease diagnosis identifying antibodies associated with lupus and connective tissue disorders, developed in partnership with Pictor, Inc.

8Cancer Screening Tests
CategoryCancer Screening Service
Description

Comprehensive cancer screening services for early detection across multiple cancer types offered through Protean's CAP/CLIA-certified laboratory; supports physicians and patients with early cancer detection.

9Cancer Consultations
CategoryTelemedicine Oncology Consultation Service
Description

Expert oncology consultations for cancer patients including diagnosis confirmation, treatment option identification, and clinical trial eligibility assessment, available via telemedicine and direct patient access.

10CRO and Research Services
CategoryContract Research Organization Services
Description

Contract research services including CLIA development, clinical trial assay support, companion diagnostics development, methylation and epigenetics testing, and collaborative research opportunities for pharmaceutical, biotechnology, and academic partners.

11Rapid Lung Panel
CategoryLung Cancer Diagnostic Test
Description

Rapid testing panel for lung cancer diagnostics providing quick turnaround for NSCLC assessment as part of Protean's clinical laboratory test menu.

12Epigenetic Profiling Test
CategoryEpigenetic Cancer Diagnostic Test
Description

Test analyzing epigenetic changes and methylation patterns for cancer characterization and research applications as part of Protean's precision oncology test menu.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-09-24
Description

Partnership to launch CDX Prostate (ClarityDX Prostate) in the United States for men at risk of aggressive prostate cancer. The test uses AI-powered learning models to generate risk scores. Protean's CLIA-certified laboratory in Orlando performs the testing. This is a major milestone for Nanostics to expand US market access.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-09-19
Description

Collaboration to develop and validate the Pictor PictHealth Extractable Nuclear Antigen (ENA) IgG Multiplex ELISA for autoimmune disease diagnosis. Protean will develop the assay which identifies antibodies associated with lupus and connective tissue disorders. Partnership supports development of other products for rapid and affordable diagnostic solutions.

3Aventa Genomics (Joint Venture with Arima Genomics)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-04
Description

Aventa Genomics is a joint venture between Arima Genomics and Protean BioDiagnostics to commercialize 3D genomics-based tests. The Aventa FusionPlus test is the first clinical application, detecting gene fusions across 361 genes with 100-1000x signal amplification. Joint venture combines Arima's technology expertise with Protean's clinical laboratory capabilities.

proteanbiodx.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-22
Description

Protean is Travera's first Center of Excellence for Rapid Therapy Guidance testing. Partnership brings treatment options to advanced carcinoma patients by determining response to specific drugs using live tumor cell screening. Indicated for 39 cancer types and 100+ FDA-approved therapies. Patients receive no-cost access through Protean MAPS platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-11
Description

Collaboration on DelPHI project with Roche to accelerate access to precision oncology for community-based oncology programs. Research published comparing variant annotation software solutions including Roche's navify Mutation Profiler.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-10
Description

Strategic partnership to introduce HDPCR-based NSCLC (non-small cell lung cancer) assay in the US through early access program. The assay addresses barriers to advanced diagnostics due to cost, slow turnaround times, and inadequate tissue samples. Florida is targeted as the state accounts for approximately 10% of cancer incidence in the US.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-02-23
Description

Research collaboration to demonstrate advantages of Biocept's Target Selector assay kit for EGFR mutation determination in non-small cell lung cancer patients. Study focused on tumor sample analysis.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2020-09-14
Description

CEO Anthony Magliocco joined Diaceutics' Expert Advisory Panel powering its industry-changing diagnostic network DxRx. Diaceutics is building a diagnostic network for precision medicine.

9UCF Business Incubation Program
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-03
Description

Protean moved headquarters to Orlando and joined the UCF Business Incubation Program's Lake Nona site. Program supports innovation companies with resources for growth. Company committed to creating jobs in the Orlando area.

proteanbiodx.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-06-11
Description

Partnership to commercialize advanced AI-based diagnostics for US pathology market with initial focus on improving quality of prostate cancer pathology diagnosis in urology practices. Dr. Magliocco participated as panelist at Precision Medicine Leaders Summit on digital pathology impact.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-03-11
Description

Original company launch associated with USF campus. Company showcased at USF Connect. Dr. Magliocco served as Clinical Associate Professor at USF College of Medicine.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Precision oncology company offering comprehensive genomic profiling (NeXT Personal) with emphasis on ultra-sensitive detection of variants and fusions. Closely comparable technology positioning to Protean's MAPS and Aventa FusionPlus, with similar focus on solid-tumor fusion detection.

TypeBroad incumbent
Description

Cell-free DNA testing company with oncology franchise (Signatera tumor-informed MRD) and partnerships in hereditary cancer risk testing. Comparable to Protean on blood-based oncology testing and hereditary risk (Risk MAPS), but at much larger scale across multiple disease areas.

TypeBroad incumbent
Description

Genomic diagnostics company with oncology franchise (Decipher Prostate, Afirma thyroid) using whole-transcriptome and methylation-based assays. Comparable to Protean on methylation/epigenetics testing and prostate cancer diagnostics (CDX Prostate competitive set).

4Tempus Labs
TypeBroad incumbent
Description

AI-enabled precision medicine company offering multi-modal NGS profiling, digital pathology, and clinical trial matching at scale. Competes with Protean's MAPS offering in oncology profiling, AI clinical trial matching, and decision support, though at a substantially larger footprint.

TypeBroad incumbent
Description

Specialized oncology reference laboratory offering comprehensive genomic profiling, liquid biopsy, and pathology services to community oncologists. Comparable target customer base to Protean and overlapping test menu including NGS and methylation profiling.

TypeDirect peer
Description

Clinical diagnostic lab offering NGS-based hereditary cancer testing (particularly with its Beacon carrier and cancer panels) and oncology profiling. Comparable to Protean on whole-exome hereditary risk (Risk MAPS) and precision oncology testing, with broader test menu.

TypeBroad incumbent
Description

Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx) for solid tumors, with national lab operations and biopharma companion-Dx partnerships. Directly comparable to Protean as a clinical NGS and molecular profiling lab serving oncologists, but at vastly larger scale and with broader payer coverage.

TypeDirect peer
Description

Precision oncology company offering comprehensive molecular profiling (MI Profile, MI Cancer Seek), ADAPT tissue-based functional profiling, and AI-driven trial matching. Closely comparable to Protean across multi-omic profiling, functional therapy guidance, and AI trial matching, with broader commercial scale.

TypeBroad incumbent
Description

Large diagnostics company offering Cologuard and the Oncotype DX franchise, with growing precision oncology menu including liquid biopsy. Comparable to Protean on hereditary cancer risk and oncology molecular diagnostics, though focused on screening and minimum residual disease.

TypeBroad incumbent
Description

Specialist in liquid biopsy and comprehensive genomic profiling (Guardant360, Guardant Reveal). Comparable to Protean in precision oncology testing with strong focus on blood-based assays, AI, and biopharma partnerships; much larger scale and capital base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protean BioDiganostics Inc

Precision Oncology Clinical Laboratory Servicesproteanbiodx.com

Protean BioDiagnostics is a CAP/CLIA-certified precision oncology laboratory in Orlando, Florida, operating the proprietary Protean MAPS platform that integrates multi-omic cancer profiling, AI-powered clinical trial matching, telemedicine decision support, and hereditary risk assessment for community oncologists, hospitals, and patients.

What Protean BioDiganostics Inc does

Protean BioDiagnostics Inc is a privately held precision oncology diagnostics company founded by Dr. Anthony M. Magliocco and headquartered in Orlando, Florida, where it operates a CAP/CLIA-certified high-complexity clinical laboratory. The company delivers advanced cancer diagnostic testing, hereditary cancer risk assessment, and treatment-decision support primarily to community-based oncologists, hospital and health-system laboratories, cancer patients, and pharmaceutical/CRO partners. Its proprietary platform, Protean MAPS (Multi-Omic Analysis and Precision Medicine System), integrates multiple diagnostic modalities — tissue testing, liquid biopsy, genetic testing, methylation/epigenetic analysis, and digital pathology imaging — with telemedicine-backed decision support and AI clinical trial matching, and is positioned as the only comprehensive precision medicine system explicitly designed for community-based cancer patients.

The technology stack is largely assembled through strategic partnerships and licensing rather than wholly internal development. Core offerings include Risk MAPS (whole exome sequencing-based hereditary risk assessment), Aventa FusionPlus (a 3D genomics clinical test for gene fusions across 361 genes, developed via the Aventa Genomics joint venture with Arima Genomics), CDX Prostate (AI-powered prostate cancer risk scoring via Nanostics' ClarityDX platform), HDPCR NSCLC Assay (ChromaCode multiplexing), Travera Rapid Therapy Guidance (functional profiling of live tumor cells against FDA-approved therapies), and the Pictor ENA IgG Multiplex ELISA for autoimmune disease. Additional capabilities include variant annotation pipelines interoperating with Roche NAVIFY, SOPHiA DDM, QIAGEN Clinical Insight Interpret, and Genoox, as well as a CLIA Digital Pathology Imaging Laboratory using computer-vision-based image analysis.

The company generates revenue primarily on a fee-for-service laboratory testing basis, billing physicians, hospitals, insurance, and patients per test with quote-based pricing that is not publicly disclosed. A secondary revenue stream comes from contract research organization (CRO) services covering CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology clients. Protean employs 51-100 staff, holds state laboratory licensure in Florida, California, and New York, and has operated with minimal disclosed external capital — a single disclosed funding round of $330,000 in 2019 — supplemented by non-dilutive support from the Florida SBDC at UCF and the UCF Business Incubation Program at Lake Nona.

Protean BioDiganostics Inc firmographics

Firmographics
Name
Protean BioDiganostics Inc
Legal name
Protean BioDiagnostics Inc
Website
https://proteanbiodx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Protean BioDiagnostics is a CAP/CLIA-certified precision oncology laboratory in Orlando, Florida, operating the proprietary Protean MAPS platform that integrates multi-omic cancer profiling, AI-powered clinical trial matching, telemedicine decision support, and hereditary risk assessment for community oncologists, hospitals, and patients.
Ownership category
akta.pro rank

Protean BioDiganostics Inc industry classification

Industry
Product category
Precision Oncology Clinical Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Precision oncology diagnostics
  • Cancer profiling services
  • Clinical laboratory testing
  • Hereditary cancer screening
  • Companion diagnostics development

Where Protean BioDiganostics Inc is headquartered

Location

Headquarters

HQ city
Orlando
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Protean BioDiganostics Inc business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Clinical Laboratory Testing Services: Protean operates a CAP/CLIA-accredited, high-complexity laboratory performing cancer diagnostic tests for physicians, hospitals, and patients. Revenue is generated through fee-for-service laboratory testing billed to healthcare providers, insurance, and patients.
  2. Genetic Risk Assessment Testing: Risk MAPS™ hereditary cancer testing services using cheek swab samples with whole exome sequencing analysis, billed as laboratory services.
  3. Research Services: CRO services including CLIA development, clinical trials support, and companion diagnostics development for pharmaceutical and biotechnology partners.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goClinical laboratory testing services - quote-based pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Protean BioDiganostics Inc product offering

Product offering

Core offering

Protean BioDiagnostics operates a CAP/CLIA-certified clinical laboratory in Orlando, Florida, that delivers precision oncology diagnostic testing and cancer profiling through its proprietary Protean MAPS platform. The company sells cancer screening, hereditary genetic testing (Risk MAPS), AI-powered prostate cancer risk assessment (CDX Prostate), 3D genomics gene fusion testing (Aventa FusionPlus), lung cancer diagnostics (HDPCR NSCLC Assay), functional therapy guidance (Travera), autoimmune diagnostics (Pictor ENA), and telemedicine-backed oncology consultations. It also provides CRO services including CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology partners.

Product overview

Protean BioDiagnostics offers Protean MAPS as the core comprehensive cancer profiling platform that integrates health screening, diagnostics, treatment guidance, and telemedicine-backed decision support. The platform encompasses multiple specialized products: Risk MAPS for hereditary cancer risk assessment via whole exome sequencing; CDX Prostate (via Nanostics partnership) for AI-powered prostate cancer risk scoring; Aventa FusionPlus (joint venture with Arima Genomics) as the first 3D genomics test for solid tumors; HDPCR NSCLC Assay (with ChromaCode) for rapid lung cancer diagnostics; Travera Rapid Therapy Guidance for treatment response profiling; and Pictor ENA IgG Multiplex ELISA for autoimmune diagnostics. Services include cancer consultations, CRO services, research services, methylation/epigenetics testing, CLIA development, and clinical trials support. All services are delivered through their CAP/CLIA-certified laboratory in Orlando, Florida.

Differentiator

Problem solved

Functional benefit

Brands

  • Protean MAPS: Proprietary comprehensive cancer profiling system integrating screening, diagnostics, treatment guidance, and telemedicine decision support for community-based cancer patients.
  • Risk MAPS

Products and services

  • Protean MAPS Proprietary cancer profiling system that incorporates the highest quality tests available and delivers rapid results with decision support and precision oncology guidance for all cancer types; includes telemedicine, virtual tumor boards, and AI clinical trial matching for oncologists and patients.
  • Risk MAPS Hereditary Cancer Testing Whole exome sequencing-based hereditary cancer risk assessment offering unprecedented coverage of the human genome for cancer prevention and treatment planning; cheek swab sample collection enables at-home or in-office testing for patients and at-risk individuals.
  • CDX Prostate (ClarityDX Prostate) Blood-based AI-powered diagnostic test for men at risk of aggressive prostate cancer, used as a reflex test following elevated PSA or abnormal DRE; uses biological data, clinical information, and machine learning models to generate risk scores. Performed in Protean's CLIA-certified Orlando laboratory.
  • Aventa FusionPlus First 3D genomics clinical test detecting gene fusions, translocations, and rearrangements across 361 genes from FFPE tumor tissue using spatial proximity preservation for 100-1000x signal amplification; developed via the Aventa Genomics joint venture between Arima Genomics and Protean.
  • HDPCR NSCLC Assay Non-small cell lung cancer assay based on ChromaCode's High Definition PCR (HDPCR) multiplexing technology delivering rapid turnaround and clinically relevant markers for lung cancer diagnostics; addresses cost, turnaround, and tissue sample barriers in NSCLC.
  • Travera Rapid Therapy Guidance Functional profiling test that uses tissue or fluid to screen live tumor cells against approved anti-cancer therapies; indicated for 39 different cancers and 100+ FDA-approved therapies to guide treatment selection for advanced carcinoma patients.
  • Pictor PictHealth ENA IgG Multiplex ELISA Next-generation multiplexed ELISA test for autoimmune disease diagnosis identifying antibodies associated with lupus and connective tissue disorders, developed in partnership with Pictor, Inc.
  • Cancer Screening Tests Comprehensive cancer screening services for early detection across multiple cancer types offered through Protean's CAP/CLIA-certified laboratory; supports physicians and patients with early cancer detection.
  • Cancer Consultations Expert oncology consultations for cancer patients including diagnosis confirmation, treatment option identification, and clinical trial eligibility assessment, available via telemedicine and direct patient access.
  • CRO and Research Services Contract research services including CLIA development, clinical trial assay support, companion diagnostics development, methylation and epigenetics testing, and collaborative research opportunities for pharmaceutical, biotechnology, and academic partners.
  • Rapid Lung Panel Rapid testing panel for lung cancer diagnostics providing quick turnaround for NSCLC assessment as part of Protean's clinical laboratory test menu.
  • Epigenetic Profiling Test Test analyzing epigenetic changes and methylation patterns for cancer characterization and research applications as part of Protean's precision oncology test menu.

Quantifiable outcome

  • Aventa FusionPlus detected potentially actionable variants in half of previously characterized tumor specimens with no known actionable driver
  • +1 more outcomes

Companies that use Protean BioDiganostics Inc

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Protean BioDiganostics Inc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature8 records

Protean BioDiganostics Inc partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Nanostics Inc.coreTechnology or Integration · 24 September 2024Partnership to launch CDX Prostate (ClarityDX Prostate) in the United States for men at risk of aggressive prostate cancer. The test uses AI-powered learning models to generate risk scores. Protean's CLIA-certified laboratory in Orlando performs the testing. This is a major milestone for Nanostics to expand US market access.
  • Pictor, Inc.coreTechnology or Integration · 19 September 2024Collaboration to develop and validate the Pictor PictHealth Extractable Nuclear Antigen (ENA) IgG Multiplex ELISA for autoimmune disease diagnosis. Protean will develop the assay which identifies antibodies associated with lupus and connective tissue disorders. Partnership supports development of other products for rapid and affordable diagnostic solutions.
  • Aventa Genomics (Joint Venture with Arima Genomics)coreStrategic or Co-development Partner · 4 October 2023Aventa Genomics is a joint venture between Arima Genomics and Protean BioDiagnostics to commercialize 3D genomics-based tests. The Aventa FusionPlus test is the first clinical application, detecting gene fusions across 361 genes with 100-1000x signal amplification. Joint venture combines Arima's technology expertise with Protean's clinical laboratory capabilities.
  • TraveracoreTechnology or Integration · 22 August 2023Protean is Travera's first Center of Excellence for Rapid Therapy Guidance testing. Partnership brings treatment options to advanced carcinoma patients by determining response to specific drugs using live tumor cell screening. Indicated for 39 cancer types and 100+ FDA-approved therapies. Patients receive no-cost access through Protean MAPS platform.
  • RochecoreTechnology or Integration · 11 August 2023Collaboration on DelPHI project with Roche to accelerate access to precision oncology for community-based oncology programs. Research published comparing variant annotation software solutions including Roche's navify Mutation Profiler.
  • ChromaCodecoreTechnology or Integration · 10 August 2023Strategic partnership to introduce HDPCR-based NSCLC (non-small cell lung cancer) assay in the US through early access program. The assay addresses barriers to advanced diagnostics due to cost, slow turnaround times, and inadequate tissue samples. Florida is targeted as the state accounts for approximately 10% of cancer incidence in the US.
  • BioceptminorStrategic or Co-development Partner · 23 February 2021Research collaboration to demonstrate advantages of Biocept's Target Selector assay kit for EGFR mutation determination in non-small cell lung cancer patients. Study focused on tumor sample analysis.
  • DiaceuticsminorGTM or Marketing Partner · 14 September 2020CEO Anthony Magliocco joined Diaceutics' Expert Advisory Panel powering its industry-changing diagnostic network DxRx. Diaceutics is building a diagnostic network for precision medicine.
  • UCF Business Incubation ProgramcoreStrategic or Co-development Partner · 3 September 2020Protean moved headquarters to Orlando and joined the UCF Business Incubation Program's Lake Nona site. Program supports innovation companies with resources for growth. Company committed to creating jobs in the Orlando area.
  • NucleaicoreTechnology or Integration · 11 June 2019Partnership to commercialize advanced AI-based diagnostics for US pathology market with initial focus on improving quality of prostate cancer pathology diagnosis in urology practices. Dr. Magliocco participated as panelist at Precision Medicine Leaders Summit on digital pathology impact.
  • University of South Florida (USF)minorStrategic or Co-development Partner · 11 March 2019Original company launch associated with USF campus. Company showcased at USF Connect. Dr. Magliocco served as Clinical Associate Professor at USF College of Medicine.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Protean BioDiganostics Inc competitors and assessment

Company assessment

Direct peers

  • Personalis: Precision oncology company offering comprehensive genomic profiling (NeXT Personal) with emphasis on ultra-sensitive detection of variants and fusions. Closely comparable technology positioning to Protean's MAPS and Aventa FusionPlus, with similar focus on solid-tumor fusion detection.
  • Fulgent Genetics: Clinical diagnostic lab offering NGS-based hereditary cancer testing (particularly with its Beacon carrier and cancer panels) and oncology profiling. Comparable to Protean on whole-exome hereditary risk (Risk MAPS) and precision oncology testing, with broader test menu.
  • Caris Life Sciences: Precision oncology company offering comprehensive molecular profiling (MI Profile, MI Cancer Seek), ADAPT tissue-based functional profiling, and AI-driven trial matching. Closely comparable to Protean across multi-omic profiling, functional therapy guidance, and AI trial matching, with broader commercial scale.

Broad incumbents

  • Natera: Cell-free DNA testing company with oncology franchise (Signatera tumor-informed MRD) and partnerships in hereditary cancer risk testing. Comparable to Protean on blood-based oncology testing and hereditary risk (Risk MAPS), but at much larger scale across multiple disease areas.
  • Veracyte: Genomic diagnostics company with oncology franchise (Decipher Prostate, Afirma thyroid) using whole-transcriptome and methylation-based assays. Comparable to Protean on methylation/epigenetics testing and prostate cancer diagnostics (CDX Prostate competitive set).
  • Tempus Labs: AI-enabled precision medicine company offering multi-modal NGS profiling, digital pathology, and clinical trial matching at scale. Competes with Protean's MAPS offering in oncology profiling, AI clinical trial matching, and decision support, though at a substantially larger footprint.
  • NeoGenomics: Specialized oncology reference laboratory offering comprehensive genomic profiling, liquid biopsy, and pathology services to community oncologists. Comparable target customer base to Protean and overlapping test menu including NGS and methylation profiling.
  • Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx) for solid tumors, with national lab operations and biopharma companion-Dx partnerships. Directly comparable to Protean as a clinical NGS and molecular profiling lab serving oncologists, but at vastly larger scale and with broader payer coverage.
  • Exact Sciences: Large diagnostics company offering Cologuard and the Oncotype DX franchise, with growing precision oncology menu including liquid biopsy. Comparable to Protean on hereditary cancer risk and oncology molecular diagnostics, though focused on screening and minimum residual disease.
  • Guardant Health: Specialist in liquid biopsy and comprehensive genomic profiling (Guardant360, Guardant Reveal). Comparable to Protean in precision oncology testing with strong focus on blood-based assays, AI, and biopharma partnerships; much larger scale and capital base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Protean BioDiganostics Inc social profiles

Digital presence

Protean BioDiganostics Inc compliance and trust

Trust signal

Compliance5 records

Protean BioDiganostics Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protean BioDiganostics Inc leadership team

Management profile

Number of profiles

Profiles7 records

Protean BioDiganostics Inc subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Protean BioDiganostics Inc funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protean BioDiganostics Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protean BioDiganostics Inc

What does Protean BioDiganostics Inc do?

Protean BioDiagnostics operates a CAP/CLIA-certified clinical laboratory in Orlando, Florida, that delivers precision oncology diagnostic testing and cancer profiling through its proprietary Protean MAPS platform. The company sells cancer screening, hereditary genetic testing (Risk MAPS), AI-powered prostate cancer risk assessment (CDX Prostate), 3D genomics gene fusion testing (Aventa FusionPlus), lung cancer diagnostics (HDPCR NSCLC Assay), functional therapy guidance (Travera), autoimmune diagnostics (Pictor ENA), and telemedicine-backed oncology consultations. It also provides CRO services including CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology partners.

Is Protean BioDiganostics Inc a public or private company?

Protean BioDiganostics Inc is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Protean BioDiganostics Inc founded?

Protean BioDiganostics Inc was founded in 2019. It employs 1 to 10 people.

Where is Protean BioDiganostics Inc based?

Protean BioDiganostics Inc is headquartered in Orlando, United States, in the North America region.

How does Protean BioDiganostics Inc make money?

Three revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are genetic Risk Assessment Testing and research Services.

Who are Protean BioDiganostics Inc's main competitors?

Direct peers on record are Personalis, Fulgent Genetics and Caris Life Sciences. Broad incumbents are Natera, Veracyte, Tempus Labs, NeoGenomics, Foundation Medicine, Exact Sciences and Guardant Health.

Does Protean BioDiganostics Inc have an API?

No public API is recorded for Protean BioDiganostics Inc.

What industry is Protean BioDiganostics Inc in?

Protean BioDiganostics Inc's product category is Precision Oncology Clinical Laboratory Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogNanostics and Protean BioDiagnostics Partner to Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the United StatesNanostics and Protean BioDiagnostics announced a partnership to offer CDX Prostate in the United States, a reflex test that generates a risk score for aggressive prostate cancer. The test uses biological data, clinical information, and AI-powered learning models, and Protean performs testing in its CLIA-certified Orlando lab. In Canada, the test is available through Nanostics' lab in Edmonton and CDL Laboratories in Quebec.PR NewswireChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.ChromaCode and Protean BioDiagnostics announced a partnership to introduce an HDPCR-based NSCLC assay via Protean's early access program. The assay detects all NCCN-recommended variants in under 24 hours with >99% NGS concordance. Protean plans to add it to its Protean MAPS platform.Business Wire BlogBiocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer PatientsBiocept and Protean BioDiagnostics announced a research collaboration to test Biocept's Target Selector EGFR assay for determining EGFR status in non-small cell lung cancer patients. The assay requires 50% less tumor input than most commercial assays, and Protean plans to validate the analytical performance of a laboratory-developed test under CAP requirements.